News
From Eli Lilly’s David Ricks to Pfizer Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
FEATURED STORIES
Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well as Dyne, Wave, Solid and Sarepta near the regulatory finish line.
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
AstraZeneca posted two mid-stage wins at the 2022 San Antonio Breast Cancer Symposium on Thursday, touting the efficacy of capivasertib and camizestrant against breast cancer.
Compass’ twin clinical updates regarding its lead candidate spotlight the promise of psychedelic medicine.
Instil Bio is discontinuing the development of its unmodified tumor-infiltrating lymphocyte (TIL) therapeutic, ITIL-168, and laying off 60% of its staff.
Those who work in the biopharma industry often see more setbacks than successes. To understand how to overcome failures, BioSpace spoke with two experts on coping with setbacks and staying positive.
Sanofi has terminated its global development and commercialization pact with Revolution Medicines, Inc. for their SHP2 inhibitor drug candidate,
Novartis reported Thursday that a Phase III trial of iptacopan met its primary endpoint in paroxysmal nocturnal hemoglobinuria (PNH) - the company’s second win in this indication in as many months.
Vertex Pharmaceuticals agreed to a collaboration deal with Entrada Therapeutics. The two companies announced a collaboration to develop an intracellular Endosomal Escape Vehicle.
Relmada’s investigational NDMA receptor channel blocker, REL-1017, failed to meet its primary endpoint in major depressive disorder in the Phase III RELIANCE I trial.
With $47 million in hand, Dantari launched Thursday to advance its Targeted High-capacity Drug Conjugate technology – its take on an antibody-drug conjugate - for solid tumors.
AVROBIO is planning a Phase II/III registrational trial for its Gaucher Disease Type 3 (GD3) gene therapy candidate, AVR-RD-02, in 2023.